Atracurium

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Atracurium
Accession Number
DB13295
Type
Small Molecule
Groups
Approved, Experimental, Investigational
Description
Not Available
Synonyms
Not Available
Categories
UNII
2GQ1IRY63P
CAS number
64228-79-1
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,10-Phenanthroline1,10-Phenanthroline may decrease the neuromuscular blocking activities of Atracurium.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Atracurium is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Atracurium.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Atracurium.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Atracurium is combined with 5-methoxy-N,N-dimethyltryptamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Atracurium.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Atracurium.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Atracurium.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Atracurium.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Atracurium.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Atracurium
ATC Codes
M03AC04 — Atracurium

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2CompletedTreatmentRadical Mastectomy1
2CompletedNot AvailableIntraocular Pressure1
2, 3Active Not RecruitingTreatmentIntubation, Endotracheal / Premedication1
2, 3CompletedTreatmentCerebral Hypoperfusion / Intubation, Endotracheal / Premedication1
3CompletedDiagnosticPostoperative pain1
4CompletedDiagnosticAtracurium / Cefazolin / Morphine / Nadroparin / Obese1
4CompletedPreventionKidney Diseases / Prostate Hypertrophy1
4CompletedSupportive CarePost-Operative Nausea and Vomiting (PONV) / Postoperative pain1
4CompletedSupportive CareQuality of Ocular Akinesia (Onset and Duration)1
4CompletedTreatmentAbdominal Compliance / Neuromuscular Blockade / Regional Anesthesia1
4CompletedTreatmentTracheal Intubation1
4Not Yet RecruitingOtherPatients Undergoing Laparoscopic Surgery1
4Not Yet RecruitingTreatmentMyoclonus1
4Unknown StatusTreatmentAnaesthesia therapy1
Not AvailableCompletedPreventionGeneral Surgery1
Not AvailableCompletedSupportive CareRobot-Assisted Laparoscopic Radical Prostatectomy1
Not AvailableCompletedTreatmentPost-Operative Nausea and Vomiting (PONV)1
Not AvailableCompletedTreatmentPostoperative paralytic ileus1
Not AvailableNot Yet RecruitingSupportive CareColorectal Cancers1
Not AvailableNot Yet RecruitingSupportive CareEndoscopic Sinus Surgery1
Not AvailableNot Yet RecruitingTreatmentNeuromuscular Blockade1
Not AvailableRecruitingNot AvailableUrologic Diseases1
Not AvailableTerminatedNot AvailableAnaesthesia therapy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on June 23, 2017 14:39 / Updated on November 02, 2019 03:10